Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 30, 2022
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
Tue, March 29, 2022
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
[ Tue, Mar 29th 2022
] - WOPRAI
Judah Frommer Maintained (ABOS) at Buy with Decreased Target to $17 on, Mar 29th, 2022
Judah Frommer of Credit Suisse, Maintained "Acumen Pharmaceuticals, Inc." (ABOS) at Buy with Decreased Target from $26 to $17 on, Mar 29th, 2022.
Judah has made no other calls on ABOS in the last 4 months.
There is 1 other peer that has a rating on ABOS. Out of the 1 peers that are also analyzing ABOS, 0 agree with Judah's Rating of Hold.
This is the rating of the analyst that currently disagrees with Judah
- Geoff Meacham of "B of A Securities" Upgraded from Hold to Strong Buy and Decreased Target to $14 on, Friday, January 21st, 2022
